Shots:

• Protagonist to receive $25M upfront- $1.0B as development- regulatory & commercial milestones & royalties on product sales with rights to co-detail both products. Janssen to get exclusive WW rights to develop & commercialize both candidates and will pay certain costs and milestones for advancing preclinical candidates through P-I
• In 2017- the companies entered into an agreement to co-develop & commercialize PTG-200 for Crohn's disease & Janssen will be responsible for its all development & commercializing activities post P-II completion
• Protagonist’s PTG-200 is an oral gut-restricted IL-23 receptor antagonist- a targeted therapy for inflammatory bowel disease (IBD) with the expected onset of P-II study in H1’19

Ref: Protagonist | Image: Janssen